Pluri Inc., a biotechnology company, has recently been granted a new U.S. patent for a unique method of expanding immune cells through the use of their proprietary technology. The company’s 3D cell expansion technology creates an environment that mimics the natural lymph node-like setting within the human body where immune cells thrive. By utilizing this innovative approach, Pluri ensures that the expanded immune cells maintain their integrity, functionality, and therapeutic efficacy.
The patented technology provided by Pluri addresses key challenges faced by current allogeneic cell therapies, including donor cell availability and scalability issues. This breakthrough offers a promising solution to the increasing demand for advanced cell-based therapies used in treating immune disorders and neurodegenerative diseases. The new business division called PluriCDMO, offering cell therapy manufacturing services as a contract development and manufacturing organization (CDMO), further solidifies Pluri’s presence in the biotechnology industry and underscores their dedication to advancing cell-based therapies on a global scale.
Yaky Yanay, the CEO and President of Pluri, expressed confidence in their technology and expertise, emphasizing their commitment to developing cutting-edge medical treatments. This groundbreaking achievement marks a significant advancement in the field of immune cell expansion and is expected to meet the rising global demand for advanced cell-based therapies. By leveraging their proprietary technology, Pluri aims to revolutionize allogeneic cell therapy and improve patient outcomes worldwide.
